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ABSTRACT 115 
 116 
Background: The European Position Paper on Rhinosinusitis and Nasal Polyps (EP3OS) incorporates 117 
symptomatic, endoscopic and radiologic criteria in the clinical diagnosis of chronic rhinosinusitis (CRS), while 118 
in epidemiological studies, the definition is based on symptoms only. We aimed to assess the reliability and 119 
validity of a symptom based definition of CRS using data from the GA2LEN European survey.  120 
Methods: On two separate occasions, 1700 subjects from 11 centers provided information on symptoms of CRS, 121 
allergic rhinitis and asthma. CRS was defined by the epidemiological EP3OS symptom criteria. The difference in 122 
prevalence of CRS between two study points, the standardized absolute repeatability and the chance corrected 123 
repeatability (kappa) were determined. In two centers 342 participants underwent nasal endoscopy. The 124 
association of symptom-based CRS with endoscopy and self-reported doctor-diagnosed CRS was assessed.  125 
Results: There was a decrease in prevalence of CRS between the two study phases, and this was consistent 126 
across all centers (-3.0%, 95% CI: -5.0 to -1.0%, I2 =0). There was fair to moderate agreement between the two 127 
occasions (kappa = 39.6). Symptom-based CRS was significantly associated with positive endoscopy in 128 
nonallergic subjects, and with self-reported doctor-diagnosed CRS in all subjects, irrespective of the presence of 129 
allergic rhinitis. 130 
Conclusion: Our findings suggest that a symptom-based definition of CRS, according to the epidemiological 131 
part of the EP3OS criteria, has a moderate reliability over tim , is stable between study centers, is not influenced 132 
by the presence of allergic rhinitis, and is suitable for the assessment of geographic variation in prevalence of 133 
CRS.  134 
 135 
Abstract Word Count: 250 136 
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INTRODUCTION 137 
Chronic rhinosinusitis (CRS), a disease defined as chronic inflammation of the nose and paranasal sinuses, has a 138 
considerable impact on morbidity and quality of life. There are varying estimates of disease prevalence based on 139 
a limited amount of data (1-4), and to date, no pan-European epidemiological study has been undertaken. The 140 
paucity of comparable and reliable data is in part related to the lack of uniformly accepted diagnostic criteria for 141 
CRS. Although a number of guidelines and consensus documents have been developed, considerable differences 142 
in diagnostic criteria and the lack of an accepted gold standard diagnosis make it difficult to make comparisons.  143 
Upper airway diseases present with a variable pattern of common symptoms such as nasal obstruction and 144 
discharge, making the epidemiological diagnosis of CRS difficult to differentiate from allergic and nonallergic 145 
rhinitis based on symptomatic grounds only. Moreover, not all patients presenting with symptoms meeting CRS 146 
criteria have evidence of disease if diagnosis is complemented with nasal endoscopy and CT. The 2007 EP3OS 147 
guideline (5) incorporates symptomatic, endoscopic and radiologic criteria in the clinical diagnosis of CRS. 148 
However, as nasal endoscopy and CT are difficult to apply in large-scale epidemiological studies, the EP3OS 149 
document defines CRS by symptoms only, when used in epidemiological studies. The repeatability and the 150 
validity of the EP3OS criteria have not yet been validated extensively.  151 
Recently, the Global Allergy and Asthma European Network of Excellence (GA²LEN) initiated a large 152 
epidemiological study comprising a postal survey (the GA²LEN Survey) followed by a case-control study (the 153 
GA²LEN Survey Follow-Up), on allergy, asthma and upp r airway disease across Europe. In this study, 154 
diagnosis of CRS is based on a questionnaire for symptoms forming part of the EP3OS diagnostic criteria. The 155 
current study aims to validate this by reporting the repeatability of the epidemiological EP3OS symptom criteria, 156 
and by describing the relationship of symptom criteria and self-reported doctor-diagnosed CRS with findings 157 
from nasal endoscopy.  158 
 159 
METHODS 160 
Study design 161 
In a first cross-sectional phase (the GA²LEN Survey), 11 participating centers sent a questionnaire by mail to a 162 
random sample of at least 3000 subjects aged 15 to 75 years, with up to three attempts to elicit a response. 163 
Samples were identified by random sampling from a population based local sampling frame.  164 
The questionnaire was newly developed for the diagnosis of chronic rhinosinusitis (Table 1). A positive 165 
diagnosis of chronic rhinosinusitis was based on symptoms as defined in the 2007 EP3OS epidemiological 166 
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criteria (Table 1); additionally, subjects were asked if a doctor had ever told whether the subject had CRS 167 
(further referred to as ‘self-reported doctor-diagnosed CRS’). Asthma was defined as reporting ‘having ever had 168 
asthma’ and at least one of the following symptoms in the last 12 months: 1) wheeze or whistling in the chest; or 169 
2) waking up with chest tightness, shortness of breath or an attack of coughing. Allergic rhinitis was defined by 170 
the self reported history of ‘nasal allergy’.  171 
In a second phase (the GA²LEN Survey Follow-Up), each center invited 120 randomly selected subjects with 172 
asthma, 120 with CRS, 40 with asthma and CRS and 120 with neither asthma or CRS for a clinical study visit 173 
with further investigations among which a questionnaire including the same questions as those described above 174 
for the postal survey.   175 
Nasal endoscopy 176 
In two centers (Ghent and Amsterdam), each participant in the Follow-Up phase was invited to undergo nasal 177 
endoscopy. Nasal endoscopy was performed, blinded to symptom status, by otorhinolaryngology specialists or 178 
residents using routine clinical rigid 30° endoscopes. An endoscopy positive for rhinosinusitis was defined, 179 
based on the EP3OS criteria, as presence of polyps, presence of oedema in the middle meatus or presence of 180 
thick purulent discharge in the middle meatus, at either nasal side.  181 
Statistical methods 182 
All data available to the coordinating center that had undergone full quality control by November 1st 2009 were 183 
included in this analysis. The prevalences of CRS, each of the symptoms of CRS, asthma and allergic rhinitis in 184 
the Survey and Follow-Up were estimated using data only from participants who had taken part in both. As the 185 
sample in the Follow-Up phase was selected based on disease in the Survey sample (and therefore had higher 186 
prevalences of asthma, CRS and both compared to the general population), prevalence estimates were 187 
standardized, for both CRS and asthma, to the original sampled population by using inverse sampling probability 188 
weights. The standardized difference in prevalence of disease between the two phases was estimated for each 189 
center and as an overall estimate (8). Variation of this difference between centers was estimated (Wald chi-190 
square test for heterogeneity) and the I-squared heterogeneity measure was computed (9). Absolute repeatability 191 
(10), standardized to account for the high prevalence of asthma, CRS and both in the Follow-Up Phase, and 192 
Cohen’s kappa (κ) statistics were derived, with confidence intervals calculated using the delta method with the 193 
normalizing transformation log (1 - κ).  194 
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The odds ratios of having CRS symptoms by endoscopy results or by self-reported doctor-diagnosed CRS were 195 
derived and tested with Pearson chi square test. To assess whether these associations were similar in subjects 196 
with and without current allergic rhinitis (defined as self-reported nasal allergy or hay fever, and sneezing, runny 197 
or blocked nose in the absence of a cold in the last 12 months), analyses were stratified by current allergic 198 
rhinitis, the Breslow-Day test was used to test for interaction, and the Mantel-Haenszel weighted odds ratio was 199 
calculated. Binomial confidence intervals according to Clopper and Pearson were calculated around proportions. 200 
All statistical analyses were carried out using Stata Version 11 (StataCorp, College Station, TX, USA) and SPSS 201 
Version 15 (SPSS Inc., Chicago, IL, USA). 202 
 203 
RESULTS 204 
Eleven centers in seven countries provided data from baseline and follow-up surveys to the coordinating center 205 
by November 2009. One center which had not yet completed the study was excluded. A total of 36790 subjects 206 
had completed the postal questionnaire, and 1700 subjects had been seen in the follow-up clinical visit. In this 207 
group, 652 were controls, 469 had asthma but no sinusitis, 411 had sinusitis but no asthma, 168 had asthma and 208 
sinusitis. Of these, 50.1% were female, the median age was 48.7 years (IQR 36.8 to 59.6 years), and the median 209 
time between postal survey and clinical visits was 287 days (IQR 205 to 359 days). 210 
Results are based on the subjects who had taken part in both phases of the study (n = 1700). Table 2 shows the 211 
standardized difference in prevalence between the two study phases, the absolute repeatability (standardized for 212 
disease prevalence) and the unstandardized kappa statistic, for CRS, asthma, allergic rhinitis, and some of their 213 
related symptoms. Figure 1 illustrates the standardized difference in prevalence between the two study phases for 214 
the outcomes CRS, asthma and allergic rhinitis in each of the participating centers. 215 
The prevalence of symptom-based CRS, estimated from the second phase, was lower than that obtained in the 216 
first phase (-3.0%; 95% CI -5.0 to -1.0%), and this difference was similar in all centers (I2 = 0). Standardized 217 
absolute repeatability of symptom-based CRS was 91.8%, and the unstandardized kappa was 39.6. All of the 218 
individually reported symptoms that contributed to the symptom-based definition of CRS showed a pattern 219 
similar to that of CRS.  220 
The prevalence of self-reported doctor-diagnosed CRS was lower than symptom-based CRS, with a marginally 221 
higher kappa (48.8). The standardized difference in prevalence showed an overall increase in prevalence in the 222 
second phase, with significant heterogeneity between centers (I2 = 52.0; p=0.028). By comparison, the 223 
prevalence of wheezing with breathlessness showed a non-significant (p=0.18) fall between the two study phases 224 
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with significant variation between centers (I2 = 58.9; p=0.0095). The unstandardized kappa (54.6) showed a 225 
moderate agreement. The prevalence of asthma showed no significant standardized difference between the 226 
baseline and clinical follow-up, with non-significant variation of this between centers (I2 = 41.5; p=0.082). The 227 
reporting of a history of ‘hay fever or nasal allergies’ showed no significant difference in prevalence between the 228 
two study phases, a standardized repeatability similar to that for CRS, and an unstandardized kappa (72.8) 229 
indicating good agreement. 230 
Association of symptoms with endoscopy and self-reported doctor-diagnosed CRS 231 
Three hundred and forty-two participants in Ghent and Amsterdam underwent nasal endoscopy. Table 3 shows 232 
the associations of symptom-based CRS with endoscopy and self-reported doctor–diagnosed CRS, stratified for 233 
current allergic rhinitis. Overall, 61.7% (95% CI: 50.3 - 72.3%) of symptom-positive subjects had a positive 234 
endoscopy, and 38.0% (32.3 - 44.1%) of symptom-negative subjects had a positive endoscopy. Of positive 235 
endoscopies, 33.6%  (26.0 – 41.7%) had CRS symptoms, and 83.9% (77.9-88.8) of negative endoscopies had no 236 
CRS symptoms. 31.4% (21.8 – 42.3) of symptom-positive and 11.1% (7.7 – 15.4%) of symptom-negative 237 
subjects had a self-reported doctor-diagnosed CRS. Symptom-based CRS was significantly associated with a 238 
positive endoscopy (OR 2.62; 95%CI [1.57 - 4.39]; p < 0.001) and with middle meatal purulent secretions and 239 
middle meatal oedema. The association of symptom-based CRS to a positive endoscopy was stronger in subjects 240 
without current allergic rhinitis (OR 3.78; p<0,001) compared to subjects with allergic rhinitis (OR 1.45; p = 241 
0.437), and the Mantel-Haenszel-corrected OR was comparable with the uncorrected OR (OR 2.41 [1.43 - 4.05], 242 
p<0,001) (Table 3). The Breslow-Day test showed no significant differences between odds ratios of each 243 
subgroup. Symptom-based CRS was associated with a self-reported doctor-diagnosed CRS (OR 3.67 [2.03 - 244 
6.60], p<0.001). This association was not modified by the presence of allergy (adjusted OR 3.62 [1.97 - 6.63], 245 
Breslow-Day p=0,871). 246 
 247 
DISCUSSION 248 
The revised EP3OS consensus document provided diagnostic criteria for CRS in 2007, and we have applied 249 
these criteria in a two phase, multi-center, questionnaire based cross-sectional epidemiological study, the 250 
GA²LEN Survey and the GA²LEN Survey Follow-UpEndoscopic findings characteristic of CRS (as defined by 251 
the EP3OS criteria) and the reporting of doctor-diagnosed CRS was used to assess the validity of the reported 252 
symptoms for defining CRS in this setting.  253 
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We used three parameters to assess reliability of the CRS questionnaire: standardized difference in prevalence, 254 
standardized absolute repeatability and unstandardized kappa statistic. When using general population surveys to 255 
describe between center differences in chronic disease prevalence, a prevalence estimate that is stable over time 256 
is needed, even though individual changes (disease incidence and disease remission) may be occurring within the 257 
population. The absence of change in prevalence implies that, at population level, the number of subjects who 258 
are asymptomatic in the first phase but have symptoms in the second phase is equivalent to the number of those 259 
with symptoms in the first phase who report no symptoms in the second phase. We observed a decrease in 260 
prevalence of CRS between the two occasions. We also observed a decrease in prevalence for ‘wheezing with 261 
breathlessness’, a commonly used symptom question in respiratory epidemiology. The magnitude of the 262 
difference for CRS was equivalent to that seen for ‘wheezing with breathlessness’ and most importantly showed 263 
no variation between centers. This means that there is no evidence that the broad interpretation of geographical 264 
variation in prevalence of disease using this instrument will be affected (that is, the error is constant across 265 
populations). 266 
Absolute repeatability was high for all questions, and to some extent this is not surprising as within subject 267 
agreement for low prevalence conditions is likely to be solely due to chance. Unstandardized repeatability 268 
(Cohen’s κ) was fair to moderate for CRS questions and  for symptom-based CRS definition, whereas it was 269 
moderate to good for asthma and nasal allergy. Cohen’s kappa is a widely accepted measure to assess chance 270 
corrected agreement (11) but it has been argued that in questionnaire development for assessing symptoms in 271 
population based studies (where the prevalence of the outcome is low) survey items should not be rejected on the 272 
basis of kappa alone (10). Other parameters should be considered, including change in prevalence and measures 273 
of validity against clinical criteria.  274 
Development of instruments suitable for the epidemiological investigation of CRS is hampered by the lack of an 275 
easily measurable gold standard definition of disease. We compared symptom criteria to endoscopy and to self-276 
reported doctor-diagnosed CRS, which are assumed to be highly specific, but not sensitive, for chronic 277 
rhinosinusitis. We demonstrated significant associations of the symptom criteria with positive endoscopy and 278 
doctor-diagnosed CRS. Of subjects who had positive symptoms, 62% had a positive endoscopy, whereas 38% of 279 
symptom-negative patients had a positive endoscopy. As patients in this study were required to have chronic 280 
symptoms in the last 12 months but not necessarily at the time of endoscopy, we expect that a small proportion 281 
of endoscopy-negative patients may have had a positive endoscopy during active symptoms and vice versa. To 282 
our knowledge, this study is the first to document endoscopy in asymptomatic subjects.  283 
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In line with work of Stankiewicz (12) investigating CT and endoscopy in CRS patients, we observe that only a 284 
proportion of symptom-positive patients had a positive endoscopy. However, in that study, only 29% of 285 
participants had a positive endoscopy, while 62% of our symptom-positive subjects had a positive endoscopy. 286 
This difference could be explained by less strict symptom criteria, and the exclusion of nasal polyp patients and 287 
patients with purulence on rhinoscopy. In a large hospital based study in Istanbul, Tahamiler (13) reports that in 288 
768 patients with CRS fulfilling the EP3OS symptom criteria, 31.3% of allergic patients and 24.7% of non-289 
allergic patients had a positive nasal endoscopy. This is a much smaller proportion than in our study 290 
(respectively 58% and 65%), but the reason for the difference is unclear, as this study used even less strict 291 
criteria for positivity of endoscopy.  292 
In the diagnosis of CRS, controversy exists whether or not to corroborate positive symptoms with endoscopy and 293 
CT (14). The EP3OS criteria propose a confirmation by either CT or endoscopy. As it is not possible to include 294 
CT in epidemiological studies involving healthy subjects, we can only hypothesize that some of our participants 295 
with positive symptoms but negative endoscopy may have had radiographic evidence of disease. In fact, in a 296 
study comparing CT and endoscopy using a proprietary scoring system in CRS patients (15), 65% of endoscopy 297 
negative patients had radiographic evidence of disease. In another study (12), this proportion was 36%. 298 
Extrapolating these data to our population, we can estimate that 76% to 87% of our symptom-based CRS 299 
diagnoses would be confirmed by endoscopy or CT had both been available.  300 
The study by Tahamiler suggests that the association of symptom-based CRS with objective markers of disease 301 
is not greatly influenced by the presence of allergic rhinitis. However there is overlap in the symptoms 302 
associated with each condition, particularly for nasal obstruction and rhinorrhoea (16-18). Therefore, we might 303 
expect a weaker association of symptom-based CRS with objective markers of disease in subjects with allergic 304 
rhinitis. We addressed this question by stratifying our analyses for current allergic rhinitis. The strength of the 305 
association of a positive endoscopy with CRS symptoms was weaker in presence of allergic rhinitis, although we 306 
found no statistically significant evidence for this (Breslow-Day test for interaction, p = 0,074). However, it has 307 
been shown that the statistical power for testing interaction is too low in many epidemiological studies (19). 308 
Although our observations could be explained by an overlap of CRS and allergic rhinitis symptoms, endoscopic 309 
findings such as oedema can also be present in both diseases. This may account for a high proportion (49,3%) of 310 
positive endoscopies in CRS-negative allergic rhinitis patients. In contrast with endoscopy, symptom-based CRS 311 
was associated with self-reported doctor-diagnosed CRS, irrespective of the presence of allergic rhinitis. Taken 312 
together, these findings suggest that a symptom-based definition of CRS is stable, irrespective of the presence of 313 
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allergic rhinitis, and that positivity of the endoscopic criteria may be influenced by the presence of allergic 314 
rhinitis. Further research of the specificity of symptom criteria and endoscopy in relation to radiologic changes is 315 
warranted.  316 
 317 
CONCLUSION 318 
We have for the first time assessed the reliability of the symptom-based EP3OS definition for epidemiological 319 
diagnosis of chronic rhinosinusitis. Our findings suggest that a symptom-based definition of CRS has a moderate 320 
reliability over time, is stable between study centers, is not influenced by the presence of allergic rhinitis, and 321 
suitable for the epidemiological assessment of geographic variation in prevalence of CRS.  322 
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 Table 1: Instruments used in the Ga²len Survey and Survey Follow-Up: EP3OS criteria for the diagnosis of 362 
chronic rhinosinusitis, and excerpts from the questionnaire. 363 
 364 
 365 
EP3OS criteria for diagnosis of chronic rhinosinusitis 
o Presence of two or more of the following symptoms: 
• Nasal blockage, obstruction or congestion 
• Nasal discharge (either anterior or posterior nasal drip) 
• Facial pain or pressure 
• Reduction or loss of smell 
One of which should be blockage or discharge 
Symptoms should be present during > 12 weeks without complete resolution 
AND EITHER: 
o Endoscopic signs of  
• Polyps, and /or 
• Mucopurulent discharge, primarily from middle meatus, and/ or 
• Oedema or obstruction primarily in middle meatus 
o CT changes: mucosal changes within the ostiomeatal complex and / or sinuses 
 
Survey questionnaire  
For assessing CRS as per EP3OS 
o Has your nose been blocked for more than 12 weeks during the last 12 months? 
o Have you had pain or pressure around the forehead, nose or eyes for more than 12 weeks during the last 12 months? 
o Have you had discoloured nasal discharge or discoloured mucus in the throat for more than 12 weeks during the last 12 months? 
o Has your sense of smell been reduced or absent for more than 12 weeks during the last 12 months? 
Additional 
o Has a doctor ever told you that you have chronic sinusitis or nasal polyps? 
o Do you have any nasal allergies, including hay fever? 
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Table 2: Standardized change in prevalence between Survey and Follow-Up, standardized absolute 
repeatability and unstandardized kappa, for questionnaire items and for symptom-defined chronic 
rhinosinusitis and asthma. Between-center heterogeneity is expressed as I². SOB = shortness of breath. 
Standardized difference in prevalence 
 Tests for 
heterogeneity 
Absolute 
repeatability 
Kappa 
Outcome N 
Standardized 
prevalence in 
survey (%) 
Diff. (%) 95% CI p I
2
 p value   
Chronic rhinosinusitis 1700 9.3 -3.0 [-5.0 to -1.0] 0.003 0.0 0.570 91.8 39.6 
Blocked nose 1687 13.3 1.3 [-4.8 to 7.3] 0.680 52.5 0.026 84.7 45.4 
Pain or pressure 1691 7.2 -3.1 [-5.0 to -1.2] 0.002 50.5 0.034 93.0 35.7 
Discoloured nasal discharge 1687 6.8 -1.5 [-2.7 to -0.3] 0.012 45.6 0.057 93.3 33.5 
Reduced sense of smell 1683 6.9 -1.0 [-1.9 to -0.1] 0.034 55.3 0.018 95.4 53.0 
Doctor-diagnosed CRS 1685 2.9 5.7 [0.2 to 11.2] 0.040 52.0 0.028 92.3 48.8 
Asthma 1700 8.0 1.3 [-0.1 to 2.7] 0.066 41.5 0.082 96.5 82.3 
Wheezing with SOB 1602 13.3 -3.8 [-9.3 to 1.8] 0.180 58.9 0.001 89.6 54.6 
Nasal allergy 1618 41.8 0.1 [-1.8 to 2.0] 0.900 8.5 0.360 92.0 72.8 
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Table 3: Associations of symptom-based CRS with endoscopy and self-reported doctor-diagnosed 
CRS, stratified for current allergic rhinitis (n = 342). Interaction effects were tested with Breslow-
Day’s test. AR = allergic rhinitis. 
 
 
Crude odds ratio 
Subjects without 
current AR 
Subjects with 
current AR 
Breslow 
Day test 
Mantel-Haenszel adjusted 
odds ratio 
 OR 95% CI p (chi²) OR 95% CI OR 95% CI p adj. OR 95% CI p 
Midde meatal findings            
   Purulent secretions  3.36 [1.55 - 7.31] 0.003 4.30 [1.58 - 11.7] 2.33 [0.67 - 8.17] 0.454 3.29 [1.49 - 7.25] 0.003 
   Oedema 2.63 [1.58 - 4.37] <0.001 3.67 [1.81 - 7.45] 1.46 [0.68 - 3.12] 0.080 2.36 [1.41 - 3.94] 0.001 
Positive endoscopy 2.62 [1.57 - 4.38] <0.001 3.78 [1.84 - 7.75] 1.45 [0.67 - 3.13] 0.074 2.41 [1.43 - 4.05] 0.001 
Doctor-diagnosed CRS 3.66 [2.03 - 6.60] <0.001 3.79 [1.71 - 8.43] 3.43 [1.37 - 8.60] 0.871 3.62 [1.97 - 6.63] <0.001 
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Figure 1: Standardized difference in prevalence between Survey and Follow-Up for each center 
(squares) and for the whole sample (diamonds), for CRS, asthma and allergic rhinitis.  
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